Citius pharmaceuticals, inc. reports fiscal third quarter 2024 financial results and provides business update

Granted fda approval of lymphir™ for the treatment of cutaneous t-cell lymphoma completed merger of oncology subsidiary with tenx keane; citius oncology expected to begin trading on nasdaq on august 13, 2024, under ticker ctor achieved primary and secondary endpoints of mino-lok® phase 3 trial cranford, n.j. , aug. 12, 2024 /prnewswire/ -- citius pharmaceuticals, inc. ("citius pharma" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal third quarter 2024 ended june 30, 2024.
CTXR Ratings Summary
CTXR Quant Ranking